Shanghai Institute Of Biological Products clinical trials

Acquired by Sinopharm, Nov 2010 · source ↗

The registry lists 34 studies whose lead sponsor is Shanghai Institute Of Biological Products. 14 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 23, 2026.

Studies

Recruiting first, then most recently updated. Showing 34 of 34. All Sinopharm studies →

• Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term InfantsNot yet recruitingNCT07363837Phase 1/2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell CarcinomaRecruitingNCT06194656Phase 2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and AboveNot yet recruitingNCT07327398Phase 2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and AboveRecruitingNCT07302256Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.RecruitingNCT06298071Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor PatientsRecruitingNCT06990464Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.RecruitingNCT07205198Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.RecruitingNCT06298058Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.RecruitingNCT06512116Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy IndividualsRecruitingNCT06932523Phase 1/2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor PatientsRecruitingNCT06985368Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the CongoNot yet recruitingNCT07253675Phase 2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trial of SIBP-A16 Injection in Healthy AdultsRecruitingNCT07106918Early Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live VaccineRecruitingNCT06771479Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 MonthsCompletedNCT06399003Phase 3

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.CompletedNCT06342349Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Study of An Adjuvanted Inactivated H7N9 Influenza VaccineCompletedNCT03755427Phase 2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza VaccineCompletedNCT03369808Phase 1/2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trial of A Quadrivalent Influenza VaccineCompletedNCT03744104Phase 3

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Study Exploring Efficacy of Peginterferon in Patients With Herpes ZosterCompletedNCT05492591Phase 2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Study Comparing SIBP-04 and Bevacizumab in Healthy Male SubjectsCompletedNCT04135898Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years OldCompletedNCT05158777Phase 3

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.CompletedNCT05203601Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung CancerCompletedNCT05318443Phase 3

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCLCompletedNCT04361279Phase 3

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast CancerCompletedNCT03989037Phase 3

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic HyperuricemiaCompletedNCT05302388Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 YearsCompletedNCT04072497Phase 1/2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• Clinical Trial of Quadrivalent Influenza Virus Split VaccineCompletedNCT04363359Phase 2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, LiveCompletedNCT05161845Phase 4

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 YearsCompletedNCT05138705Phase 4

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• A Clinical Trial of PEGIFNα1b in Chinese Healthy AdultsCompletedNCT05639803Phase 1

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 VaccineCompletedNCT01336166Phase 2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm

• Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in InfantsCompletedNCT01494740Phase 2

  Sponsor listed in the registry: Shanghai Institute Of Biological Products · First submitted after Shanghai Institute Of Biological Products became part of Sinopharm